Incannex Healthcare (IXHL) vs. Its Peers Head-To-Head Analysis

Incannex Healthcare (NASDAQ:IXHL) is one of 897 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Incannex Healthcare to similar companies based on the strength of its analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Profitability

This table compares Incannex Healthcare and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-25.62%	-24.46%
Incannex Healthcare Competitors	-2,378.17%	-221.76%	-16.01%

Analyst Recommendations

This is a summary of recent ratings and price targets for Incannex Healthcare and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	2	0	1	0	1.67
Incannex Healthcare Competitors	7747	13833	25665	1031	2.41

Incannex Healthcare presently has a consensus target price of $18.00, suggesting a potential upside of 576.69%. As a group, “Pharmaceuticals” companies have a potential upside of 29.03%. Given Incannex Healthcare’s higher possible upside, analysts clearly believe Incannex Healthcare is more favorable than its competitors.

Insider and Institutional Ownership

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

Incannex Healthcare has a beta of 6.97, meaning that its stock price is 597% more volatile than the S&P 500. Comparatively, Incannex Healthcare’s competitors have a beta of -4.12, meaning that their average stock price is 512% less volatile than the S&P 500.

Valuation & Earnings

This table compares Incannex Healthcare and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Incannex Healthcare	$90,000.00	-$19.30 million	-1.57
Incannex Healthcare Competitors	$4.49 billion	$3.15 billion	547.90

Incannex Healthcare’s competitors have higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Incannex Healthcare competitors beat Incannex Healthcare on 9 of the 13 factors compared.

About Incannex Healthcare

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.